MSDT

AcronymDefinition
MSDTMaster Scuba Diver Trainer (PADI instructor level)
MSDTMelanie Stewart Dance Theatre (est. 1984; Philadelphia, PA)
MSDTMicrosoft Support Diagnostic Tool
MSDTManagement Style Diagnostic Test
MSDTMultiscale Decision Theory (aka multiscale decision making)
MSDTMean Supply Downtime
References in periodicals archive ?
Patients were classified into four groups according to their MRD status after the first course of chemotherapy and donor type: (1) patients undergoing MSDT with positive MRD after the first course of chemotherapy ( n = 14), (2) patients undergoing MSDT without positive MRD after the first course of chemotherapy ( n = 17), (3) patients undergoing haplo-SCT with positive MRD after the first course of chemotherapy ( n = 48), and (4) patients undergoing haplo-SCT without positive MRD after the first course of chemotherapy ( n = 66).
In MSDT settings, patients with positive MRD after the first course of chemotherapy had higher incidences of relapse (32.3 [+ or -] 9.7% vs.
Patients were classified into four groups according to their MRD status after the second course of chemotherapy and donor type: (1) patients undergoing MSDT with positive MRD after the second course of chemotherapy ( n = 7), (2) patients undergoing MSDT without positive MRD after the second course of chemotherapy ( n = 24), (3) patients undergoing haplo-SCT with positive MRD after the second course of chemotherapy ( n = 34), and (4) patients undergoing haplo-SCT without positive MRD after the second course of chemotherapy ( n = 80).
In MSDT settings, patients with positive MRD after the second course of chemotherapy had higher incidences of relapse (57.1 [+ or -] 3.6% vs.
To explore the impact of pretransplant MRD on outcomes in patients receiving haplo-SCT and MSDT, patients were classified into four groups according to their MRD status pretransplantation and donor type: (1) patients undergoing MSDT with positive MRD pretransplantation ( n = 8), (2) patients undergoing MSDT without positive MRD pretransplantation ( n = 23), (3) patients undergoing haplo-SCT with positive MRD pretransplantation ( n = 33), and (4) patients undergoing haplo-SCT without positive MRD pretransplantation ( n = 81).
Data showed that in MSDT settings, patients with positive MRD pretransplant had higher CIR (50.0 [+ or -] 9.7% vs.
Patients were classified into four groups: patients with (Group I, n = 6) or without (Group II, n = 25) persistent positive MRD from postinduction to pretransplant in MSDT settings, patients with (Group III, n = 13) or without (Group IV, n = 101) persistent positive MRD from postinduction to pretransplant in haplo-SCT settings.
Patients with persistent positive MRD undergoing MSDT (Group I, n = 6) had the highest incidence of relapse, followed by patients with persistent positive MRD undergoing haplo-SCT (Group III, n = 13), patients without persistent positive MRD undergoing haplo-SCT (Group IV, n = 101), and patients without persistent MRD undergoing MSDT (Group II, n = 25) (66.7 [+ or -] 9.2% vs.
In conclusion, patients with persistent positive MRD postinduction and pretransplant had higher CIR, lower LFS, and OS than those without persistent positive MRD both in MSDT and haplo-HSCT settings.
In this study, we showed the negative effects of MRD after the first and second courses of chemotherapy on transplant outcomes in patients who underwent MSDT but not those receiving haplo-SCT.
Further analysis showed negative effects of MRD after the first and second chemotherapy on transplant outcomes in the MSDT subgroup.
In this study, we also demonstrated a negative association of positive pre-MRD with poor prognosis in patients receiving MSDT but not those who underwent haplo-SCT.